EyePoint Pharmaceuticals | Evaluate

February 14, 2022

Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea

The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?

Clearside’s long-acting eye project shows promise

But data are early, and other groups are also developing less frequent injections for wet AMD.

November 06, 2018

Clearside’s future clouds over

After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.

December 23, 2015

Psivida eyes uveitis approval

September 29, 2014

After fourth look FDA sees its way clear to approve Alimera’s Iluvien

March 05, 2012

Iluvien launch details awaited following Alimera's European win

January 06, 2012

Small caps produce clear winners and losers in 2011

November 14, 2011

Alimera and pSivida strike out

October 10, 2011

Event - Alimera and pSivida hope Iluvien will be second time lucky

March 29, 2011

Interest in Australian pharma sector continues to grow

February 04, 2011

Alimera clears some of the muddle on Iluvien data

Load More